• Brad Spellberg, John Edwards, and Ashraf Ibrahim.
• Department of Medicine, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance, 1124 West Carson St. RB2, Torrance, CA 90502, USA. bspellberg@labiomed.org
• Clin. Microbiol. Rev. 2005 Jul 1;18(3):556-69.

AbstractMucormycosis is a life-threatening fungal infection that occurs in immunocompromised patients. These infections are becoming increasingly common, yet survival remains very poor. A greater understanding of the pathogenesis of the disease may lead to future therapies. For example, it is now clear that iron metabolism plays a central role in regulating mucormycosis infections and that deferoxamine predisposes patients to mucormycosis by inappropriately supplying the fungus with iron. These findings raise the possibility that iron chelator therapy may be useful to treat the infection as long as the chelator does not inappropriately supply the fungus with iron. Recent data support the concept that high-dose liposomal amphotericin is the preferred monotherapy for mucormycosis. However, several novel therapeutic strategies are available. These options include combination therapy using lipid-based amphotericin with an echinocandin or with an azole (largely itraconazole or posaconazole) or with all three. The underlying principles of therapy for this disease remain rapid diagnosis, reversal of underlying predisposition, and urgent surgical debridement.

12 keywords...

hide…